Kathleen Sakamoto
Stanford University, California Institute of Technology, University of Cincinnati, Williams College
0000-0003-0494-8838
About
Dr. Sakamoto received her B.A. from Williams College, Cum Laude in Biology and received her M.D. from the University of Cincinnati College of Medicine. She was a Pediatric resident and Hematology/Oncology fellowship at the Children’s Hospital of Los Angeles. She her Ph.D. degree at the California Institute of Technology, where she developed a new approach to cancer therapy that targets the cell’s own destruction machinery. Dr. Sakamoto is currently the Division Chief of Hematology/Oncology/Stem Cell Transplantation/Cancer Biology at Stanford University School of Medicine. She is supported by the NIH and DOD. Dr. Sakamoto has been named in Who’s Who in America and Best Doctors in America. She has received numerous awards including ASPHO Young Investigator Award in Oncology, the Western Society of Pediatric Research Young Investigator award, UCLA STOP Cancer Career Development Award, and a Leukemia and Lymphoma Society Scholar Award. Dr. Sakamoto’s research focuses on understanding the molecular regulation of hematopoiesis and how aberrancies result in diseases of hematopoiesis, including leukemia, bone marrow failure, and myeloproliferative neoplasms.
Employment
-
Stanford University Professor2011 - Present
Education
-
California Institute of Technology Ph.D.2000 - 2004
-
University of Cincinnati M.D.1981 - 1985
-
Williams College B.A.1975 - 1979
Projects & Funding
Projects & funding information is unavailable.
Publications (178)
- Immunological mechanisms and therapeutic advances in chronic myeloid leukemia Save
- Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis Save
- Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia. Save
- RSK signaling in myeloid malignancies: biology, disease dependency, and therapeutic targeting. Save
- Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia. Save
- State-transition model of time-series single-cell RNA-seq identifies gene-level origins of disease microstate stability in chronic myeloid leukemia (CML). Save
- Dendritic cell dysfunction predicts adverse prognosis in high-risk acute lymphoblastic leukemia Save
- DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL. Save
- Aberrant cell cycle regulation and osteoblastic differentiation in diamond-blackfan anemia (DBA) mesenchymal stem cells Save
- Immune Dysregulation and State-Transition Transcriptomic Signatures Underlying Pediatric Chronic Myeloid Leukemia Pathogenesis Save